Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck.

Trial Profile

A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs Cyclophosphamide (Primary) ; Indometacin (Primary) ; IRX 2 (Primary) ; Omeprazole (Primary) ; Zinc (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Sponsors Brooklyn ImmunoTherapeutics; IRX Therapeutics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 11 Sep 2017 Results published in an IRX Therapeutics media release.
    • 11 Sep 2017 According to an IRX Therapeutics media release, results from the study have been presented at the European Society for Medical Oncology (ESMO) Annual Congress 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top